Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):2183–2186. doi: 10.1128/aac.40.9.2183

Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

L E Mathes 1, K A Hayes 1, G Kociba 1
PMCID: PMC163495  PMID: 8878603

Abstract

The antiviral efficacy of prophylactic 3'-azido-3'-deoxythymidine (AZT) therapy administered by continuous infusion or intermittent injection was compared in pediatric cats infected with feline leukemia virus. A 4-week treatment regimen of AZT was initiated at -48, 8, or 96 h postinfection (p.i.). For AZT therapy begun at -48 h p.i., significant efficacy was attained when therapy was given by continuous infusion but not by intermittent injection. However, when AZT therapy was delayed until 96 h p.i., both continuous infusion and intermittent injection gave complete protection. The results suggest that intermittent AZT administration is less efficacious than continuous infusion. Higher peak AZT concentrations in plasma associated with intermittent injection compared with those associated with continuous infusion may be immunotoxic, thus reducing the drug-induced vaccine effect. Furthermore, AZT toxicity seemed to be restricted to a window of sensitivity close to the time of virus challenge because delaying the start of AZT therapy until 96 h p.i. was highly efficacious, regardless of the method of administration.

Full Text

The Full Text of this article is available as a PDF (170.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balzarini J., Pauwels R., Baba M., Herdewijn P., de Clercq E., Broder S., Johns D. G. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 1988 Mar 1;37(5):897–903. doi: 10.1016/0006-2952(88)90178-5. [DOI] [PubMed] [Google Scholar]
  2. Basham T., Rios C. D., Holdener T., Merigan T. C. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis. 1990 May;161(5):1006–1009. doi: 10.1093/infdis/161.5.1006. [DOI] [PubMed] [Google Scholar]
  3. Bilello J. A., Kort J. J., MacAuley C., Fredrickson T. N., Yetter R. A., Eiseman J. L. ZDV delays but does not prevent the transmission of MAIDS by LP-BM5 MuLV-infected macrophage-monocytes. J Acquir Immune Defic Syndr. 1992;5(6):571–576. [PubMed] [Google Scholar]
  4. Buseyne F., Rivière Y. HIV-specific CD8+ T-cell immune responses and viral replication. AIDS. 1993 Nov;7 (Suppl 2):S81–S85. doi: 10.1097/00002030-199311002-00016. [DOI] [PubMed] [Google Scholar]
  5. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995 Jan 26;332(4):201–208. doi: 10.1056/NEJM199501263320401. [DOI] [PubMed] [Google Scholar]
  6. Cheynier R., Langlade-Demoyen P., Marescot M. R., Blanche S., Blondin G., Wain-Hobson S., Griscelli C., Vilmer E., Plata F. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol. 1992 Sep;22(9):2211–2217. doi: 10.1002/eji.1830220905. [DOI] [PubMed] [Google Scholar]
  7. Chiu D. T., Duesberg P. H. The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. Genetica. 1995;95(1-3):103–109. doi: 10.1007/BF01435004. [DOI] [PubMed] [Google Scholar]
  8. Clerici M., Giorgi J. V., Chou C. C., Gudeman V. K., Zack J. A., Gupta P., Ho H. N., Nishanian P. G., Berzofsky J. A., Shearer G. M. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis. 1992 Jun;165(6):1012–1019. doi: 10.1093/infdis/165.6.1012. [DOI] [PubMed] [Google Scholar]
  9. Clerici M., Levin J. M., Kessler H. A., Harris A., Berzofsky J. A., Landay A. L., Shearer G. M. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994 Jan 5;271(1):42–46. [PubMed] [Google Scholar]
  10. Dickover R. E., Garratty E. M., Herman S. A., Sim M. S., Plaeger S., Boyer P. J., Keller M., Deveikis A., Stiehm E. R., Bryson Y. J. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA. 1996 Feb 28;275(8):599–605. [PubMed] [Google Scholar]
  11. Durand E., Le Jeunne C., Hugues F. C. Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood. N Engl J Med. 1991 Apr 11;324(15):1062–1062. doi: 10.1056/NEJM199104113241513. [DOI] [PubMed] [Google Scholar]
  12. Fazely F., Haseltine W. A., Rodger R. F., Ruprecht R. M. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr. 1991;4(11):1093–1097. [PubMed] [Google Scholar]
  13. Ferbas J., Kaplan A. H., Hausner M. A., Hultin L. E., Matud J. L., Liu Z., Panicali D. L., Nerng-Ho H., Detels R., Giorgi J. V. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis. 1995 Aug;172(2):329–339. doi: 10.1093/infdis/172.2.329. [DOI] [PubMed] [Google Scholar]
  14. Fischinger P. J., Blevins C. S., Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol. 1974 Jul;14(1):177–179. doi: 10.1128/jvi.14.1.177-179.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  16. Frick L. W., Nelson D. J. Effects of 3'-azido-3'-deoxythymidine on the deoxynucleoside triphosphate pools of cultured human cells. Adv Exp Med Biol. 1989;253B:389–394. doi: 10.1007/978-1-4684-5676-9_57. [DOI] [PubMed] [Google Scholar]
  17. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hayes K. A., Lafrado L. J., Erickson J. G., Marr J. M., Mathes L. E. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr. 1993 Feb;6(2):127–134. [PubMed] [Google Scholar]
  19. Hayes K. A., Wilkinson J. G., Frick R., Francke S., Mathes L. E. Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):114–122. [PubMed] [Google Scholar]
  20. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996 Jan 19;271(5247):324–328. doi: 10.1126/science.271.5247.324. [DOI] [PubMed] [Google Scholar]
  21. Heagy W., Crumpacker C., Lopez P. A., Finberg R. W. Inhibition of immune functions by antiviral drugs. J Clin Invest. 1991 Jun;87(6):1916–1924. doi: 10.1172/JCI115217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hoover E. A., Olsen R. G., Hardy W. D., Jr, Schaller J. P., Mathes L. E. Feline leukemia virus infection: age-related variation in response of cats to experimental infection. J Natl Cancer Inst. 1976 Aug;57(2):365–369. doi: 10.1093/jnci/57.2.365. [DOI] [PubMed] [Google Scholar]
  23. Johnson M., Caiazzo T., Molina J. M., Donahue R., Groopman J. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol. 1988 Oct;70(2):137–141. doi: 10.1111/j.1365-2141.1988.tb02454.x. [DOI] [PubMed] [Google Scholar]
  24. Kinloch-De Loës S., Hirschel B. J., Hoen B., Cooper D. A., Tindall B., Carr A., Saurat J. H., Clumeck N., Lazzarin A., Mathiesen L. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995 Aug 17;333(7):408–413. doi: 10.1056/NEJM199508173330702. [DOI] [PubMed] [Google Scholar]
  25. Lange J. M., Boucher C. A., Hollak C. E., Wiltink E. H., Reiss P., van Royen E. A., Roos M., Danner S. A., Goudsmit J. Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med. 1990 May 10;322(19):1375–1377. doi: 10.1056/NEJM199005103221907. [DOI] [PubMed] [Google Scholar]
  26. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  27. Looke D. F., Grove D. I. Failed prophylactic zidovudine after needlestick injury. Lancet. 1990 May 26;335(8700):1280–1280. doi: 10.1016/0140-6736(90)91343-9. [DOI] [PubMed] [Google Scholar]
  28. Lucey D., Milum S., Lindquist C., Andrzejewski C., Benton J., Boswell R. N. Pseudofailure of zidovudine prophylaxis after a human immunodeficiency virus-positive needlestick. J Infect Dis. 1990 Nov;162(5):1211–1212. doi: 10.1093/infdis/162.5.1211-b. [DOI] [PubMed] [Google Scholar]
  29. Lundgren B., Böttiger D., Ljungdahl-Ståhle E., Norrby E., Ståhle L., Wahren B., Oberg B. Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4(5):489–498. [PubMed] [Google Scholar]
  30. Martin L. N., Murphey-Corb M., Soike K. F., Davison-Fairburn B., Baskin G. B. Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis. 1993 Oct;168(4):825–835. doi: 10.1093/infdis/168.4.825. [DOI] [PubMed] [Google Scholar]
  31. Mathes L. E., Polas P. J., Hayes K. A., Swenson C. L., Johnson S., Kociba G. J. Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother. 1992 Dec;36(12):2715–2721. doi: 10.1128/aac.36.12.2715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. McCune J. M., Namikawa R., Shih C. C., Rabin L., Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science. 1990 Feb 2;247(4942):564–566. doi: 10.1126/science.2300816. [DOI] [PubMed] [Google Scholar]
  33. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Morrey J. D., Okleberry K. M., Sidwell R. W. Early-initiated zidovudine therapy prevents disease but not low levels of persistent retrovirus in mice. J Acquir Immune Defic Syndr. 1991;4(5):506–512. [PubMed] [Google Scholar]
  35. Mukherji E., Au J. L., Mathes L. E. Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother. 1994 Jul;38(7):1573–1579. doi: 10.1128/aac.38.7.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Munch-Petersen B. Azidothymidine inhibits mitogen stimulated growth and DNA-repair in human peripheral lymphocytes. Biochem Biophys Res Commun. 1988 Dec 30;157(3):1369–1375. doi: 10.1016/s0006-291x(88)81026-x. [DOI] [PubMed] [Google Scholar]
  37. Palmer D. L., Hjelle B. L., Wiley C. A., Allen S., Wachsman W., Mills R. G., Davis L. E., Merlin T. L. HIV-1 infection despite immediate combination antiviral therapy after infusion of contaminated white cells. Am J Med. 1994 Sep;97(3):289–295. doi: 10.1016/0002-9343(94)90012-4. [DOI] [PubMed] [Google Scholar]
  38. Pinto L. A., Sullivan J., Berzofsky J. A., Clerici M., Kessler H. A., Landay A. L., Shearer G. M. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 1995 Aug;96(2):867–876. doi: 10.1172/JCI118133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Polas P. J., Swenson C. L., Sams R., Cheney C. M., Hayes K. A., Tarr M. J., Kociba G. J., Mathes L. E. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother. 1990 Jul;34(7):1414–1421. doi: 10.1128/aac.34.7.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Rinaldo C., Huang X. L., Fan Z. F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995 Sep;69(9):5838–5842. doi: 10.1128/jvi.69.9.5838-5842.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rivière Y., McChesney M. B., Porrot F., Tanneau-Salvadori F., Sansonetti P., Lopez O., Pialoux G., Feuillie V., Mollereau M., Chamaret S. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses. 1995 Aug;11(8):903–907. doi: 10.1089/aid.1995.11.903. [DOI] [PubMed] [Google Scholar]
  42. Rowland-Jones S. L., Nixon D. F., Aldhous M. C., Gotch F., Ariyoshi K., Hallam N., Kroll J. S., Froebel K., McMichael A. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 1993 Apr 3;341(8849):860–861. doi: 10.1016/0140-6736(93)93063-7. [DOI] [PubMed] [Google Scholar]
  43. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., Corrah T. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995 Jan;1(1):59–64. doi: 10.1038/nm0195-59. [DOI] [PubMed] [Google Scholar]
  44. Ruprecht R. M., Mullaney S., Bernard L. D., Gama Sosa M. A., Hom R. C., Finberg R. W. Vaccination with a live retrovirus: the nature of the protective immune response. Proc Natl Acad Sci U S A. 1990 Jul;87(14):5558–5562. doi: 10.1073/pnas.87.14.5558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ruprecht R. M., O'Brien L. G., Rossoni L. D., Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine. Nature. 1986 Oct 2;323(6087):467–469. doi: 10.1038/323467a0. [DOI] [PubMed] [Google Scholar]
  46. Semple M., Loveday C., Weller I., Tedder R. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol. 1991 Sep;35(1):38–45. doi: 10.1002/jmv.1890350109. [DOI] [PubMed] [Google Scholar]
  47. Shaw D. R., Knight D. R., Waterman A. L., Sommadossi J. P. 3'-Azido-3'-deoxythymidine inhibition of human lymphocyte cytolytic function in vitro. Biochem Pharmacol. 1991 Jan 15;41(2):287–291. doi: 10.1016/0006-2952(91)90488-q. [DOI] [PubMed] [Google Scholar]
  48. Shearer G. M., Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today. 1996 Jan;17(1):21–24. doi: 10.1016/0167-5699(96)80564-0. [DOI] [PubMed] [Google Scholar]
  49. Simpson M. V., Chin C. D., Keilbaugh S. A., Lin T. S., Prusoff W. H. Studies on the inhibition of mitochondrial DNA replication by 3'-azido-3'-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem Pharmacol. 1989 Apr 1;38(7):1033–1036. doi: 10.1016/0006-2952(89)90245-1. [DOI] [PubMed] [Google Scholar]
  50. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. St Clair M. H., Richards C. A., Spector T., Weinhold K. J., Miller W. H., Langlois A. J., Furman P. A. 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother. 1987 Dec;31(12):1972–1977. doi: 10.1128/aac.31.12.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. St Luce S., Arts E., Geleziunas R., Bour S., Wainberg M. A. Infection of human monocyte-derived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission. J Med Virol. 1993 Sep;41(1):71–78. doi: 10.1002/jmv.1890410115. [DOI] [PubMed] [Google Scholar]
  53. Stine K. C., Tyler D. S., Stanley S. D., Bartlett J. A., Bolognesi D. P., Weinhold K. J. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. Cell Immunol. 1991 Aug;136(1):165–172. doi: 10.1016/0008-8749(91)90391-n. [DOI] [PubMed] [Google Scholar]
  54. Swenson C. L., Polas P. J., Mathes L. E. A technique for continuous intravenous infusion in cats. Lab Anim Sci. 1989 Nov;39(6):615–617. [PubMed] [Google Scholar]
  55. Tauris P., Møller B., Petersen C. M., Black F. T. Effects of 3'-azido-3'-deoxythymidine (AZT) on short-term cultured human peripheral blood lymphocytes. Eur J Clin Invest. 1989 Apr;19(2):167–171. doi: 10.1111/j.1365-2362.1989.tb00212.x. [DOI] [PubMed] [Google Scholar]
  56. Tavares L., Roneker C., Johnston K., Lehrman S. N., de Noronha F. 3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res. 1987 Jun 15;47(12):3190–3194. [PubMed] [Google Scholar]
  57. Tindall B., Carr A., Goldstein D., Penny R., Cooper D. A. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response. AIDS. 1993 Jan;7(1):127–128. doi: 10.1097/00002030-199301000-00020. [DOI] [PubMed] [Google Scholar]
  58. Tokars J. I., Marcus R., Culver D. H., Schable C. A., McKibben P. S., Bandea C. I., Bell D. M. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med. 1993 Jun 15;118(12):913–919. doi: 10.7326/0003-4819-118-12-199306150-00001. [DOI] [PubMed] [Google Scholar]
  59. Winceslaus J. HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy. Lancet. 1993 Jun 12;341(8859):1537–1537. doi: 10.1016/0140-6736(93)90675-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES